

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

C1498

RRID:CVCL_3494

Type: Cell Line

Proper Citation

BCRJ Cat# 0306, RRID:CVCL_3494

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3494

Proper Citation: BCRJ Cat# 0306, RRID:CVCL_3494

Description: Cell line C1498 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Female

Disease: Mouse leukemia

Defining Citation: [PMID:4541304](#)

Comments: Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: C1498

Cross References: CLO:CLO_0002093, ATCC:TIB-49, BCRJ:0306, Wikidata:Q54807858

ID: CVCL_3494

Vendor: BCRJ

Catalog Number: 0306

Record Creation Time: 20220427T215430+0000

Record Last Update: 20260904T012603+0000

Ratings and Alerts

No rating or validation information has been found for C1498.

No alerts have been found for C1498.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Yu J, et al. (2026) Investigating the Role of TNFSF12 in Thyroid Cancer Progression via Single-Cell RNA Sequencing and Integrated Multiomics Analyses. Mediators of inflammation, 2026(1), e4753653.

Zhang N, et al. (2025) Jab1 promotes immune evasion and progression in acute myeloid leukemia models under oxidative stress. The Journal of clinical investigation, 135(20).

Li Z, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell, 187(3), 624.

Mei D, et al. (2024) Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models. Journal for immunotherapy of cancer, 12(9).

Bassani B, et al. (2024) ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion. Cell reports, 43(2), 113794.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. Cell reports. Medicine, 5(6), 101592.

Liu Y, et al. (2023) Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways. British journal of pharmacology, 180(6), 701.

Chen C, et al. (2022) NADPH metabolism determines the leukemogenic capacity and drug resistance of AML cells. Cell reports, 39(1), 110607.

Shimizu K, et al. (2020) PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation. Molecular cell, 77(5), 937.